Us TOO launches campaign for PCa awareness month
In conjunction with September as prostate cancer awareness month, Us TOO International is launching its nationwide “SEA Blue” campaign on behalf of prostate cancer patients and their families.
In conjunction with September as prostate cancer awareness month, Us TOO International is launching its nationwide “SEA Blue” campaign on behalf of prostate cancer patients and their families.
“The SEA [support, education, and advocacy] Blue campaign is designed to reach out to those at risk, promote prostate cancer screening, and give a voice in the community to the issue of prostate cancer awareness,” said Thomas Kirk of Us TOO.
“Prostate cancer actually strikes more men than breast cancer does women each year, yet the public remains largely unaware of this serious health issue and the significance of the blue ribbon. We think it’s important, in recognition of prostate cancer awareness month, for everyone to ‘see blue’ and realize that, as pink is to breast cancer, blue is to prostate cancer.”
Us TOO’s “SEA Blue” campaign is being supported by informational materials, lapel pins, window stickers, and posters that the organization is distributing to its more than 300 local chapters around the country.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
